Ataxia telangiectasia: a review
Tóm tắt
Từ khóa
Tài liệu tham khảo
Boder E, Sedgwick RP. A familial syndrome of progressive cerebellar ataxia, oculocutaneous telangiectasia and frequent pulmonary infection: a preliminary report on 7 children, an autopsy, and a case history. Univ Southern Calif Med Bull. 1957;9:15–28.
Anheim M, Tranchant C, Koenig M. The autosomal recessive cerebellar ataxias. N Engl J Med. 2012;366(7):636–46.
Nissenkorn A, et al. Endocrine abnormalities in ataxia telangiectasia: findings from a national cohort. Pediatr Res. 2016;79(6):889–94.
Shiloh Y, Kastan MB. ATM: genome stability, neuronal development, and cancer cross paths. Adv Cancer Res. 2001;83:209–54.
Shiloh Y. ATM and related protein kinases: safeguarding genome integrity. Nat Rev Cancer. 2003;3(3):155–68.
Derheimer FA, Kastan MB. Multiple roles of ATM in monitoring and maintaining DNA integrity. FEBS Lett. 2010;584(17):3675–81.
Sedgewick RP, Boder E. In: Vinken PJ, Bruyn GW, editors. Handbook of Clinical Neurology, vol. 14. Amsterdam: North Holland Publishing; 1972.
Swift M, et al. The incidence and gene frequency of ataxia-telangiectasia in the United States. Am J Hum Genet. 1986;39(5):573–83.
Boder E. Ataxia-telangiectasia: an overview. Kroc Found Ser. 1985;19:1–63.
Hoche F, et al. Neurodegeneration in ataxia telangiectasia: what is new? What is evident? Neuropediatrics. 2012;43(3):119–29.
Boder E, Sedgwick RP. Ataxia-telangiectasia; a familial syndrome of progressive cerebellar ataxia, oculocutaneous telangiectasia and frequent pulmonary infection. Pediatrics. 1958;21(4):526–54.
Shaikh AG, et al. Disorders of upper limb movements in ataxia-telangiectasia. PLoS One. 2013;8(6):e67042.
Pearson TS. More than ataxia: hyperkinetic movement disorders in childhood autosomal recessive ataxia syndromes, vol. 6. NY: Tremor Other Hyperkinet Mov; 2016. p. 368.
Kwast O, Ignatowicz R. Progressive peripheral neuron degeneration in ataxia-telangiectasia: an electrophysiological study in children. Dev Med Child Neurol. 1990;32(9):800–7.
Sahama I, et al. Radiological imaging in ataxia telangiectasia: a review. Cerebellum. 2014;13(4):521–30.
Lin DD, et al. Cerebral abnormalities in adults with ataxia-telangiectasia. AJNR Am J Neuroradiol. 2014;35(1):119–23.
Sahama I, et al. Altered corticomotor-cerebellar integrity in young ataxia telangiectasia patients. Mov Disord. 2014;29(10):1289–98.
Sahama I, et al. Motor pathway degeneration in young ataxia telangiectasia patients: a diffusion tractography study. Neuroimage Clin. 2015;9:206–15.
Lin DD, et al. Proton MR spectroscopic imaging in ataxia-telangiectasia. Neuropediatrics. 2006;37(4):241–6.
Wallis LI, et al. Proton spectroscopy and imaging at 3 T in ataxia-telangiectasia. AJNR Am J Neuroradiol. 2007;28(1):79–83.
Volkow ND, et al. Brain glucose metabolism in adults with ataxia-telangiectasia and their asymptomatic relatives. Brain. 2014;137(Pt 6):1753–61.
Cabana MD, et al. Consequences of the delayed diagnosis of ataxia-telangiectasia. Pediatrics. 1998;102(1 Pt 1):98–100.
Lewis RF, Lederman HM, Crawford TO. Ocular motor abnormalities in ataxia telangiectasia. Ann Neurol. 1999;46(3):287–95.
Shaikh AG, et al. Gaze fixation deficits and their implication in ataxia-telangiectasia. J Neurol Neurosurg Psychiatry. 2009;80(8):858–64.
Shaikh AG, et al. Ataxia telangiectasia: a “disease model” to understand the cerebellar control of vestibular reflexes. J Neurophysiol. 2011;105(6):3034–41.
Nowak-Wegrzyn A, et al. Immunodeficiency and infections in ataxia-telangiectasia. J Pediatr. 2004;144(4):505–11.
Driessen GJ, et al. Antibody deficiency in patients with ataxia telangiectasia is caused by disturbed B- and T-cell homeostasis and reduced immune repertoire diversity. J Allergy Clin Immunol. 2013;131(5):1367–75. e9.
Kraus M, et al. Disturbed B and T cell homeostasis and neogenesis in patients with ataxia telangiectasia. J Clin Immunol. 2014;34(5):561–72.
Noordzij JG, et al. Ataxia-telangiectasia patients presenting with hyper-IgM syndrome. Arch Dis Child. 2009;94(6):448–9.
Chopra C, et al. Immune deficiency in Ataxia-Telangiectasia: a longitudinal study of 44 patients. Clin Exp Immunol. 2014;176(2):275–82.
Lockman JL, et al. The critically ill patient with ataxia-telangiectasia: a case series*. Pediatr Crit Care Med. 2012;13(2):e84–90.
Schroeder SA, Zielen S. Infections of the respiratory system in patients with ataxia-telangiectasia. Pediatr Pulmonol. 2014;49(4):389–99.
Paller AS, et al. Cutaneous granulomatous lesions in patients with ataxia-telangiectasia. J Pediatr. 1991;119(6):917–22.
Chiam LY, et al. Cutaneous granulomas in ataxia telangiectasia and other primary immunodeficiencies: reflection of inappropriate immune regulation? Dermatology. 2011;223(1):13–9.
Crawford TO, et al. Survival probability in ataxia telangiectasia. Arch Dis Child. 2006;91(7):610–1.
Bhatt JM, et al. ERS statement on the multidisciplinary respiratory management of ataxia telangiectasia. Eur Respir Rev. 2015;24(138):565–81.
McGrath-Morrow S, et al. Pulmonary function in adolescents with ataxia telangiectasia. Pediatr Pulmonol. 2008;43(1):59–66.
McGrath-Morrow SA, et al. Pulmonary function in children and young adults with ataxia telangiectasia. Pediatr Pulmonol. 2014;49(1):84–90.
Lockman JL, et al. Anesthetic and perioperative risk in the patient with Ataxia-Telangiectasia. Paediatr Anaesth. 2012;22(3):256–62.
Schroeder SA, et al. Interstitial lung disease in patients with ataxia-telangiectasia. Pediatr Pulmonol. 2005;39(6):537–43.
Stanley SE, et al. Radiation sensitivity and radiation necrosis in the short telomere syndromes. Int J Radiat Oncol Biol Phys. 2015;93(5):1115–7.
Chen RL, et al. Severe lung fibrosis after chemotherapy in a child with ataxia-telangiectasia. J Pediatr Hematol Oncol. 2002;24(1):77–9.
McGrath-Morrow SA, et al. Elevated serum IL-8 levels in ataxia telangiectasia. J Pediatr. 2010;156(4):682–4. e1.
McGrath-Morrow SA, et al. Serum interleukin-6 levels and pulmonary function in ataxia-telangiectasia. J Pediatr. 2016;171:256–261.e1.
Reiman A, et al. Lymphoid tumours and breast cancer in ataxia telangiectasia; substantial protective effect of residual ATM kinase activity against childhood tumours. Br J Cancer. 2011;105(4):586–91.
Suarez F, et al. Incidence, presentation, and prognosis of malignancies in ataxia-telangiectasia: a report from the French national registry of primary immune deficiencies. J Clin Oncol. 2015;33(2):202–8.
van Os NJ, et al. Health risks for ataxia-telangiectasia mutated heterozygotes: a systematic review, meta-analysis and evidence-based guideline. Clin Genet. 2016;90(2):105–17.
Hollestelle A, et al. Discovering moderate-risk breast cancer susceptibility genes. Curr Opin Genet Dev. 2010;20(3):268–76.
Economopoulou P, G. Dimitriadis, A. Psyrri. Beyond BRCA: New hereditary breast cancer susceptibility genes. Cancer Treat Rev. 2015. 41(1):1-8.
Thompson D, et al. Cancer risks and mortality in heterozygous ATM mutation carriers. J Natl Cancer Inst. 2005;97(11):813–22.
Renwick A, et al. ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat Genet. 2006;38(8):873–5.
Marabelli M, Cheng SC, Parmigiani G. Penetrance of ATM gene mutations in breast cancer: A meta-analysis of different measures of risk. Genet Epidemiol. 2016;40(5):425–31.
Hart RM, et al. Radiotherapeutic management of medulloblastoma in a pediatric patient with ataxia telangiectasia. Int J Radiat Oncol Biol Phys. 1987;13(8):1237–40.
DeWire MD, et al. Radiation therapy and adjuvant chemotherapy in a patient with a malignant glioneuronal tumor and underlying ataxia telangiectasia: a case report and review of the literature. J Clin Oncol. 2013;31(1):e12–4.
Hannan MA, et al. Deficiency in the repair of UV-induced DNA damage in human skin fibroblasts compromised for the ATM gene. Carcinogenesis. 2002;23(10):1617–24.
Shiloh Y. ATM: expanding roles as a chief guardian of genome stability. Exp Cell Res. 2014;329(1):154–61.
Kiuru A, et al. Assessment of targeted and non-targeted responses in cells deficient in ATM function following exposure to low and high dose X-rays. PLoS One. 2014;9(3):e93211.
Gutierrez-Enriquez S, et al. Functional consequences of ATM sequence variants for chromosomal radiosensitivity. Genes Chromosomes Cancer. 2004;40(2):109–19.
Shiloh Y, et al. G2 chromosomal radiosensitivity in families with ataxia-telangiectasia. Hum Genet. 1989;84(1):15–8.
Weissberg JB, Huang DD, Swift M. Radiosensitivity of normal tissues in ataxia-telangiectasia heterozygotes. Int J Radiat Oncol Biol Phys. 1998;42(5):1133–6.
Bernstein JL, et al. Radiation exposure, the ATM Gene, and contralateral breast cancer in the women’s environmental cancer and radiation epidemiology study. J Natl Cancer Inst. 2010;102(7):475–83.
Lefton-Greif MA, et al. Oropharyngeal dysphagia and aspiration in patients with ataxia-telangiectasia. J Pediatr. 2000;136(2):225–31.
Boder E, Sedgwick R. Ataxia telangiectasia: a review of 101 cases, in little club clinics in developmental medicine No. 8. London: Heinemann Books; 1963. p. 110–8.
Woods CG, Taylor AM. Ataxia telangiectasia in the British isles: the clinical and laboratory features of 70 affected individuals. Q J Med. 1992;82(298):169–79.
Moin M, et al. Ataxia-Telangiectasia in Iran: Clinical and Laboratory Features of 104 Patients. Pediatr Neurol. 2007;37(1):21–8.
Schubert R, Reichenbach J, Zielen S. Growth factor deficiency in patients with ataxia telangiectasia. Clin Exp Immunol. 2005;140(3):517–9.
Kieslich M, et al. Extracerebellar MRI-lesions in ataxia telangiectasia go along with deficiency of the GH/IGF-1 axis, markedly reduced body weight, high ataxia scores and advanced age. Cerebellum. 2010;9(2):190–7.
Lefton-Greif MA, et al. Assessment of impaired coordination between respiration and deglutition in children and young adults with ataxia telangiectasia. Dev Med Child Neurol. 2016;58(10):1069–75.
Voss S, et al. Growth retardation and growth hormone deficiency in patients with Ataxia telangiectasia. Growth Factors. 2014;32(3–4):123–9.
Ehlayel M, Soliman A, De Sanctis V. Linear growth and endocrine function in children with ataxia telangiectasia. Indian J Endocrinol Metab. 2014;18 Suppl 1:S93–6.
Elson A, et al. Pleiotropic defects in ataxia-telangiectasia protein-deficient mice. Proc Natl Acad Sci U S A. 1996;93(23):13084–9.
Xu Y, et al. Targeted disruption of ATM leads to growth retardation, chromosomal fragmentation during meiosis, immune defects, and thymic lymphoma. Genes Dev. 1996;10(19):2411–22.
Herzog KH, et al. Requirement for Atm in ionizing radiation-induced cell death in the developing central nervous system. Science. 1998;280(5366):1089–91.
Worth PF, et al. Very mild presentation in adult with classical cellular phenotype of ataxia telangiectasia. Mov Disord. 2013;28(4):524–8.
Connelly PJ, et al. Recessive mutations in the cancer gene Ataxia Telangiectasia mutated (ATM), at a locus previously associated with metformin response, cause dysglycaemia and insulin resistance. Diabet Med. 2016;33(3):371–5.
McGrath-Morrow SA, et al. Polysomnographic values in adolescents with ataxia telangiectasia. Pediatr Pulmonol. 2008;43(7):674–9.
Mostofsky SH, et al. Judgment of duration in individuals with ataxia-telangiectasia. Dev Neuropsychol. 2000;17(1):63–74.
Vinck A, et al. Cognitive and speech-language performance in children with ataxia telangiectasia. Dev Neurorehabil. 2011;14(5):315–22.
Schmahmann JD, Sherman JC. The cerebellar cognitive affective syndrome. Brain. 1998;121(Pt 4):561–79.
Hoche F, et al. The cerebellar cognitive affective syndrome (CCAS) in children with ataxia telangiectasia (A-T). Orlando: Ataxia Investigators Meeting, National Ataxia Foundation; 2016.
Gatti R, Perlman S, et al. Ataxia-telangiectasia. In: Pagon RA, Pagon RA, editors. GeneReviews(R). Seattle: University of Washington; 1993.
Weiss B, et al. Liver disease in pediatric patients with ataxia telangiectasia: a novel report. J Pediatr Gastroenterol Nutr. 2016;62(4):550–5.
Andrade IG, et al. Risk of atherosclerosis in patients with ataxia telangiectasia. Ann Nutr Metab. 2015;66(4):196–201.
Ataxia-Telangiectasia in Children: Guidance on Diagnosis and Clinical Care. http://www.atsociety.org.uk/data/files/William/A-T_Clinical_Guidance_Document_Final.pdf . Accessed 21 Nov 2016.
Savitsky K, et al. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science. 1995;268(5218):1749–53.
Gatti RA, et al. Localization of an ataxia-telangiectasia gene to chromosome 11q22-23. Nature. 1988;336(6199):577–80.
Gilad S, et al. Ataxia-telangiectasia: founder effect among north African Jews. Hum Mol Genet. 1996;5(12):2033–7.
Telatar M, et al. Ataxia-telangiectasia: identification and detection of founder-effect mutations in the ATM gene in ethnic populations. Am J Hum Genet. 1998;62(1):86–97.
Hassin-Baer S, et al. Absence of mutations in ATM, the gene responsible for ataxia telangiectasia in patients with cerebellar ataxia. J Neurol. 1999;246(8):716–9.
Gilad S, et al. Genotype-phenotype relationships in ataxia-telangiectasia and variants. Am J Hum Genet. 1998;62(3):551–61.
Verhagen MM, et al. Presence of ATM protein and residual kinase activity correlates with the phenotype in ataxia-telangiectasia: a genotype-phenotype study. Hum Mutat. 2012;33(3):561–71.
Micol R, et al. Morbidity and mortality from ataxia-telangiectasia are associated with ATM genotype. J Allergy Clin Immunol. 2011;128(2):382–9. e1.
Taylor AM, et al. Ataxia telangiectasia: more variation at clinical and cellular levels. Clin Genet. 2015;87(3):199–208.
Sandoval N, et al. Characterization of ATM gene mutations in 66 ataxia telangiectasia families. Hum Mol Genet. 1999;8(1):69–79.
Li A, Swift M. Mutations at the ataxia-telangiectasia locus and clinical phenotypes of A-T patients. Am J Med Genet. 2000;92(3):170–7.
Bielorai B, et al. Acute lymphoblastic leukemia in early childhood as the presenting sign of ataxia-telangiectasia variant. Pediatr Hematol Oncol. 2013;30(6):574–82.
Yanofsky RA, et al. Ataxia-telangiectasia: atypical presentation and toxicity of cancer treatment. Can J Neurol Sci. 2009;36(4):462–7.
Saviozzi S, et al. A late onset variant of ataxia-telangiectasia with a compound heterozygous genotype, A8030G/7481insA. J Med Genet. 2002;39(1):57–61.
Sutton IJ, et al. Adult-onset ataxia telangiectasia due to ATM 5762ins137 mutation homozygosity. Ann Neurol. 2004;55(6):891–5.
Gazulla J, Benavente I, Sarasa Barrio M. Adult-onset ataxia-telangiectasia. A clinical and therapeutic observation. Neurologia. 2006;21(8):447–51.
Hiel JA, et al. Distal spinal muscular atrophy as a major feature in adult-onset ataxia telangiectasia. Neurology. 2006;67(2):346–9.
Alterman N, et al. Ataxia-telangiectasia: mild neurological presentation despite null ATM mutation and severe cellular phenotype. Am J Med Genet A. 2007;143(16):1827–34.
Chessa L, et al. Heterogeneity in ataxia-telangiectasia: classical phenotype associated with intermediate cellular radiosensitivity. Am J Med Genet. 1992;42(5):741–6.
Paz A, et al. SPIKE: a database of highly curated human signaling pathways. Nucleic Acids Res. 2011;39(Database issue):D793–9.
Matsuoka S, et al. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science. 2007;316(5828):1160–6.
Shiloh Y, Ziv Y. The ATM protein kinase: regulating the cellular response to genotoxic stress, and more. Nat Rev Mol Cell Biol. 2013;14(4):197–210.
Bredemeyer AL, et al. ATM stabilizes DNA double-strand-break complexes during V(D)J recombination. Nature. 2006;442(7101):466–70.
Bredemeyer AL, et al. Aberrant V(D)J recombination in ataxia telangiectasia mutated-deficient lymphocytes is dependent on nonhomologous DNA end joining. J Immunol. 2008;181(4):2620–5.
Bredemeyer AL, et al. DNA double-strand breaks activate a multi-functional genetic program in developing lymphocytes. Nature. 2008;456(7223):819–23.
Zha S, et al. ATM-deficient thymic lymphoma is associated with aberrant tcrd rearrangement and gene amplification. J Exp Med. 2010;207(7):1369–80.
Tepsuporn S, et al. Mechanisms that Can promote peripheral B-cell lymphoma in ATM-deficient mice. Cancer Immunol Res. 2014;2(9):857–66.
Schubert R, et al. Cancer chemoprevention by the antioxidant tempol in Atm-deficient mice. Hum Mol Genet. 2004;13(16):1793–802.
Reliene R, Schiestl RH. Antioxidant N-acetyl cysteine reduces incidence and multiplicity of lymphoma in Atm deficient mice. DNA Repair (Amst). 2006;5(7):852–9.
Gueven N, et al. Dramatic extension of tumor latency and correction of neurobehavioral phenotype in Atm-mutant mice with a nitroxide antioxidant. Free Radic Biol Med. 2006;41(6):992–1000.
Gilmore EC. DNA repair abnormalities leading to ataxia: shared neurological phenotypes and risk factors. Neurogenetics. 2014;15(4):217–28.
Barzilai A, Biton S, Shiloh Y. The role of the DNA damage response in neuronal development, organization and maintenance. DNA Repair (Amst). 2008;7(7):1010–27.
Vinters HV, Gatti RA, Rakic P. Sequence of cellular events in cerebellar ontogeny relevant to expression of neuronal abnormalities in ataxia-telangiectasia. Kroc Found Ser. 1985;19:233–55.
Gatti RA, Vinters HV. Cerebellar pathology in ataxia-telangiectasia: the significance of basket cells. Kroc Found Ser. 1985;19:225–32.
McGrath-Morrow SA, et al. Evaluation and management of pulmonary disease in ataxia-telangiectasia. Pediatr Pulmonol. 2010;45(9):847–59.
Eickmeier O, et al. Altered mucosal immune response after acute lung injury in a murine model of Ataxia Telangiectasia. BMC Pulm Med. 2014;14(1):93.
Shiloh Y, Tabor E, Becker Y. Colony-forming ability of ataxia-telangiectasia skin fibroblasts is an indicator of their early senescence and increased demand for growth factors. Exp Cell Res. 1982;140(1):191–9.
Metcalfe JA, et al. Accelerated telomere shortening in ataxia telangiectasia. Nat Genet. 1996;13(3):350–3.
Gatei M, et al. Ataxia-telangiectasia: chronic activation of damage-responsive functions is reduced by alpha-lipoic acid. Oncogene. 2001;20(3):289–94.
Inomata K, et al. Genotoxic stress abrogates renewal of melanocyte stem cells by triggering their differentiation. Cell. 2009;137(6):1088–99.
Shiloh Y, H.M. Lederman. Ataxia-telangiectasia (A-T): An emerging dimension of premature ageing. Ageing Res Rev. 2016;12. doi: 10.1016/j.arr.2016.05.002 .
Yang DQ, Kastan MB. Participation of ATM in insulin signalling through phosphorylation of eIF-4E-binding protein 1. Nat Cell Biol. 2000;2(12):893–8.
Yang DQ, et al. Cytoplasmic ATM protein kinase: an emerging therapeutic target for diabetes, cancer and neuronal degeneration. Drug Discov Today. 2011;16(7–8):332–8.
Ditch S, Paull TT. The ATM protein kinase and cellular redox signaling: beyond the DNA damage response. Trends Biochem Sci. 2012;37(1):15–22.
Schneider JG, et al. ATM-dependent suppression of stress signaling reduces vascular disease in metabolic syndrome. Cell Metab. 2006;4(5):377–89.
Stray-Pedersen A, et al. Alpha fetoprotein is increasing with age in ataxia-telangiectasia. Eur J Paediatr Neurol. 2007;11(6):375–80.
Chun HH, et al. Improved diagnostic testing for ataxia-telangiectasia by immunoblotting of nuclear lysates for ATM protein expression. Mol Genet Metab. 2003;80(4):437–43.
Taylor AM, Byrd PJ. Molecular pathology of ataxia telangiectasia. J Clin Pathol. 2005;58(10):1009–15.
Bower, M., Diagnostic Yield of a Targeted Next Generation Sequencing Approach in a Young Adult Population: High Frequency of Recessive Ataxias and Implentation of a Next Generation Sequencing Copy-Number Variation Algorithm. 5th Ataxia Investigators Meeting (AIM 2014), Las Vegas, NV, March 18–21, 2014
Herskind A, Greisen G, Nielsen JB. Early identification and intervention in cerebral palsy. Dev Med Child Neurol. 2015;57(1):29–36.
Salman MS, Ikeda KM. The syndrome of infantile-onset saccade initiation delay. Can J Neurol Sci. 2013;40(2):235–40.
Hellani A, et al. Pregnancy after preimplantation genetic diagnosis for ataxia telangiectasia. Mol Hum Reprod. 2002;8(8):785–8.
Verlinsky Y, et al. Preimplantation diagnosis for immunodeficiencies. Reprod Biomed Online. 2007;14(2):214–23.
Borte S, et al. Neonatal screening for severe primary immunodeficiency diseases using high-throughput triplex real-time PCR. Blood. 2012;119(11):2552–5.
Mallott J, et al. Newborn screening for SCID identifies patients with ataxia telangiectasia. J Clin Immunol. 2013;33(3):540–9.
Lavin MF, et al. Current and potential therapeutic strategies for the treatment of ataxia-telangiectasia. Br Med Bull. 2007;81–82:129–47.
Nissenkorn A, et al. Movement disorder in ataxia-telangiectasia: treatment with amantadine sulfate. J Child Neurol. 2013;28(2):155–60.
van Egmond ME, et al. Myoclonus in childhood-onset neurogenetic disorders: The importance of early identification and treatment. Eur J Paediatr Neurol. 2015;19(6):726–9.
Romano S, et al. Riluzole in patients with hereditary cerebellar ataxia: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2015;14(10):985–91.
Sadighi Akha AA, et al. Oligo-/monoclonal gammopathy and hypergammaglobulinemia in ataxia-telangiectasia. A study of 90 patients. Medicine (Baltimore). 1999;78(6):370–81.
Privette ED, et al. Healing of granulomatous skin changes in ataxia-telangiectasia after treatment with intravenous immunoglobulin and topical mometasone 0.1% ointment. Pediatr Dermatol. 2014;31(6):703–7.
Mitra A, et al. Infliximab in the treatment of a child with cutaneous granulomas associated with ataxia telangiectasia. J Am Acad Dermatol. 2011;65(3):676–7.
Pinzon-Charry A, Kimble R, Peake J. Intralesional steroids for the treatment of cutaneous granulomas in ataxia telangiectasia [abstract]. Intern Med J. 2013;43(Suppl S4):25.
Montella S, et al. Non invasive assessment of lung disease in ataxia telangiectasia by high-field magnetic resonance imaging. J Clin Immunol. 2013;33(7):1185–91.
O’Donnell AE. Bronchiectasis: which antibiotics to use and when? Curr Opin Pulm Med. 2015;21(3):272–7.
Magis-Escurra C, MH Reijers. Bronchiectasis. BMJ Clin Evid. 2015;25(2015).
Berkun Y, et al. Reversible airway obstruction in children with ataxia telangiectasia. Pediatr Pulmonol. 2010;45(3):230–5.
Miske LJ, et al. Use of the mechanical in-exsufflator in pediatric patients with neuromuscular disease and impaired cough. Chest. 2004;125(4):1406–12.
Felix E, Gimenes AC, Costa-Carvalho BT. Effects of inspiratory muscle training on lung volumes, respiratory muscle strength, and quality of life in patients with ataxia telangiectasia. Pediatr Pulmonol. 2014;49(3):238–44.
Lefton-Greif MA, et al. Safety and caregiver satisfaction with gastrostomy in patients with Ataxia Telangiectasia. Orphanet J Rare Dis. 2011;6:23.
Pommerening H, et al. Body composition, muscle strength and hormonal status in patients with ataxia telangiectasia: a cohort study. Orphanet J Rare Dis. 2015;10:155.
Ross LJ, et al. Nutritional status of patients with ataxia-telangiectasia: a case for early and ongoing nutrition support and intervention. J Paediatr Child Health. 2015;51(8):802–7.
Schoenaker MHD, et al. Treatment of acute leukemia in children with ataxia telangiectasia (A-T). Eur. J. Med. Genet. 2016;27. doi: 10.1016/j.ejmg.2016.05.012 .
Sandlund JT, et al. Pilot study of modified LMB-based therapy for children with ataxia-telangiectasia and advanced stage high grade mature B-cell malignancies. Pediatr Blood Cancer. 2014;61(2):360–2.
Ussowicz M, et al. Long-term survival after allogeneic-matched sibling PBSC transplantation with conditioning consisting of low-dose busilvex and fludarabine in a 3-year-old boy with ataxia-telangiectasia syndrome and ALL. Bone Marrow Transplant. 2013;48(5):740–1.
Beier R, et al. Allogeneic-matched sibling stem cell transplantation in a 13-year-old boy with ataxia telangiectasia and EBV-positive non-Hodgkin lymphoma. Bone Marrow Transplant. 2016;51(9):1271–4.
Shaikh AG, et al. Effects of 4-aminopyridine on nystagmus and vestibulo-ocular reflex in ataxia-telangiectasia. J Neurol. 2013;260(11):2728–35.
Haraldsson A. Immunoglobulin Treatment in Ataxia Telangiectasia. Nijmegen: Ataxia Telangiectasia Clinical Research Conference; 2014.
Yamamoto ML, et al. Intestinal bacteria modify lymphoma incidence and latency by affecting systemic inflammatory state, oxidative stress, and leukocyte genotoxicity. Cancer Res. 2013;73(14):4222–32.
The Global A-T Family Data Platform https://www.atfamilies.org/ . Accessed 21 Nov 2016.
Teive HA, et al. Ataxia-telangiectasia - A historical review and a proposal for a new designation: ATM syndrome. J Neurol Sci. 2015;355(1–2):3–6.
Crawford TO. Outcome measures of neurodegeneration in ataxia telangiectasia. Beijing: International Ataxia Telangiectasia Workshop (ATW2015); 2015.
Crawford TO, et al. Quantitative neurologic assessment of ataxia-telangiectasia. Neurology. 2000;54(7):1505–9.
Saunders-Pullman R, et al. Variant ataxia-telangiectasia presenting as primary-appearing dystonia in Canadian Mennonites. Neurology. 2012;78(9):649–57.
Churchyard A, Stell R, Mastaglia FL. Ataxia telangiectasia presenting as an extrapyramidal movement disorder and ocular motor apraxia without overt telangiectasia. Clin Exp Neurol. 1991;28:90–6.
Termsarasab P, Yang AC, Frucht SJ. Myoclonus in ataxia-telangiectasia, vol. 5. N Y: Tremor Other Hyperkinet Mov; 2015. p. 298.
Tripathi DN, et al. A new role for ATM in selective autophagy of peroxisomes (pexophagy). Autophagy. 2016;12(4):711–2.
Pan-Hammarstrom Q, et al. ATM is not required in somatic hypermutation of VH, but is involved in the introduction of mutations in the switch mu region. J Immunol. 2003;170(7):3707–16.
Lumsden JM, et al. Immunoglobulin class switch recombination is impaired in Atm-deficient mice. J Exp Med. 2004;200(9):1111–21.
Bagley J, Singh G, Iacomini J. Regulation of oxidative stress responses by ataxia-telangiectasia mutated is required for T cell proliferation. J Immunol. 2007;178(8):4757–63.
D’Souza AD, et al. Aberrant CD8(+) T-cell responses and memory differentiation upon viral infection of an ataxia-telangiectasia mouse model driven by hyper-activated Akt and mTORC1 signaling. Am J Pathol. 2011;178(6):2740–51.
Dar I, et al. Analysis of the ataxia telangiectasia mutated-mediated DNA damage response in murine cerebellar neurons. J Neurosci. 2006;26(29):7767–74.
Biton S, et al. Nuclear ATM mediates the cellular response to DNA double strand breaks in human neuron-like cells. J Biol Chem. 2006;281(25):17482–91.
Lee Y, Chong MJ, McKinnon PJ. Ataxia telangiectasia mutated-dependent apoptosis after genotoxic stress in the developing nervous system is determined by cellular differentiation status. J Neurosci. 2001;21(17):6687–93.
Sordet O, et al. Ataxia telangiectasia mutated activation by transcription- and topoisomerase I-induced DNA double-strand breaks. EMBO Rep. 2009;10(8):887–93.
Das BB, et al. Optimal function of the DNA repair enzyme TDP1 requires its phosphorylation by ATM and/or DNA-PK. Embo J. 2009;28(23):3667–80.
Alagoz M, et al. ATM deficiency results in accumulation of DNA-topoisomerase I covalent intermediates in neural cells. PLoS One. 2013;8(4):e58239.
Katyal S, et al. Aberrant topoisomerase-1 DNA lesions are pathogenic in neurodegenerative genome instability syndromes. Nat Neurosci. 2014;17(6):813–21.
Iourov IY, et al. Increased chromosome instability dramatically disrupts neural genome integrity and mediates cerebellar degeneration in the ataxia-telangiectasia brain. Hum Mol Genet. 2009;18(14):2656–69.
Cosentino C, Grieco D, Costanzo V. ATM activates the pentose phosphate pathway promoting anti-oxidant defence and DNA repair. Embo J. 2011;30(3):546–55.
Alexander A, et al. ATM signals to TSC2 in the cytoplasm to regulate mTORC1 in response to ROS. Proc Natl Acad Sci U S A. 2010;107(9):4153–8.
Zhang J, et al. ATM functions at the peroxisome to induce pexophagy in response to ROS. Nat Cell Biol. 2015;17(10):1259–69.
Biton S, Barzilai A, Shiloh Y. The neurological phenotype of ataxia-telangiectasia: solving a persistent puzzle. DNA Repair (Amst). 2008;7(7):1028–38.
Marinoglou K. The role of the DNA damage response kinase ataxia telangiectasia mutated in neuroprotection. Yale J Biol Med. 2012;85(4):469–80.
Valentin-Vega YA, et al. Mitochondrial dysfunction in ataxia-telangiectasia. Blood. 2012;119(6):1490–500.
D’Souza AD, et al. Reducing mitochondrial ROS improves disease-related pathology in a mouse model of ataxia-telangiectasia. Mol Ther. 2013;21(1):42–8.
Sharma NK, et al. Intrinsic mitochondrial DNA repair defects in ataxia telangiectasia. DNA Repair (Amst). 2014;13:22–31.
Yang Y, Herrup K. Loss of neuronal cell cycle control in ataxia-telangiectasia: a unified disease mechanism. J Neurosci. 2005;25(10):2522–9.
Levine-Small N, et al. Reduced synchronization persistence in neural networks derived from atm-deficient mice. Front Neurosci. 2011;5:46.
Vail G, et al. ATM protein is located on presynaptic vesicles and its deficit leads to failures in synaptic plasticity. J Neurophysiol. 2016;116(1):201–9.
Li J, et al. Nuclear accumulation of HDAC4 in ATM deficiency promotes neurodegeneration in ataxia telangiectasia. Nat Med. 2012;18(5):783–90.
Li J, et al. EZH2-mediated H3K27 trimethylation mediates neurodegeneration in ataxia-telangiectasia. Nat Neurosci. 2013;16(12):1745–53.
Jiang D, et al. Alteration in 5-hydroxymethylcytosine-mediated epigenetic regulation leads to Purkinje cell vulnerability in ATM deficiency. Brain. 2015;138(Pt 12):3520–36.
Raz-Prag D, et al. A role for vascular deficiency in retinal pathology in a mouse model of ataxia-telangiectasia. Am J Pathol. 2011;179(3):1533–41.
Wood LM, et al. A novel role for ATM in regulating proteasome-mediated protein degradation through suppression of the ISG15 conjugation pathway. PLoS One. 2011;6(1):e16422.
Sun X, et al. Early diagnosis of ataxia-telangiectasia using radiosensitivity testing. J Pediatr. 2002;140(6):724–31.
Ciccia A, Elledge SJ. The DNA damage response: making it safe to play with knives. Mol Cell. 2010;40(2):179–204.